Boehringer releases positive Phase III trial results of tiotropium Respimat in asthma patients

Boehringer Ingelheim has reported positive results from large-scale Phase III studies demonstrating that once-daily tiotropium delivered via the Respimat inhaler was effective and well-tolerated in patients across asthma severities.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news